江苏先声药业有限公司 SIMCERE PHARMACEUTICAL GROUP
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
China NMPA approves Simcere's Sanbexin® sublingual tablets for the treatment of Acute Ischemic Stroke 2024-12-04 18:10
World Stroke Congress | TASTE-2 significantly reduces stroke disability 2024-10-30 15:36
TASTE-2 World Stroke Congress | Sanbexin ® combined with thrombectomy significantly reduces stroke disability 2024-10-25 15:14
Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration 2024-09-14 19:43
Simcere Phar-maceuticals Presented Six Studies on Sanbexin® at ESOC 2024 2024-05-21 15:52
Findings of a Phase III Clinical Study of Sanbexin® Sublingual Tablets Published in JAMA 2024-02-21 12:26
Simcere and Connect Enter into an exclusive license and collaboration agreement for the innovative autoimmune drug Rademikibart 2023-11-23 16:04
SIMCERE PHARMA (HK.2096) Novel Inhibitor of COVID-19 3CLpro SIM0417 Received a Second Clinical Trial Approval in China 2022-05-18 11:56
SIMCERE PHARMA (HK.2096) to host 2022 R&D Day 2022-04-07 21:39
Bijoyesh Mookerjee, M.D. named Chief Medical Officer, Oncology for Simcere Pharmaceuticals 2022-02-08 10:01
Simcere and JW Pharmaceutical Announce Collaboration and License Agreement for Anti-Gout Drug Candidate URC-102 in China 2019-09-27 18:52
1